RedHill Biopharma (RDHL) Price to Book (2013 - 2025)

RedHill Biopharma (RDHL) has reported Price to Book for 13 consecutive years, with 3.56 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Price to Book rose 101.04% year-over-year to 3.56 in Q4 2025; TTM through Dec 2025 was 3.56, a 101.04% increase from a year earlier, with the FY2025 full-year figure at 3.56, up 101.04% from the prior year.
• Price to Book was 3.56 for Q4 2025 at RedHill Biopharma, up from 113.94 in the prior quarter.
• Over five years, Price to Book peaked at 39378.08 in Q2 2024 and troughed at 15376.91 in Q1 2022.
• A 5-year average of 4916.73 and a median of 269.41 in 2023 frame the typical range for Price to Book.
• Across the five-year window, Price to Book sank 390.17% in 2022 and soared 7256.78% in 2024, its largest moves.
• Over 5 years, Price to Book stood at 15315.53 in 2021, then slumped by 101.17% to 179.14 in 2022, then soared by 2651.84% to 4571.27 in 2023, then tumbled by 107.52% to 343.61 in 2024, then surged by 101.04% to 3.56 in 2025.
• The last three Price to Book figures came in at 3.56 (Q4 2025), 113.94 (Q2 2025), and 343.61 (Q4 2024), per Business Quant data.